Are Sage Therapeutics Inc. (SAGE) stocks a prudent buy?

Sage Therapeutics Inc. [SAGE] stock is trading at $37.45, up 0.75%. An important factor to consider is whether the stock is rising or falling in short-term value. The SAGE shares have gain 6.63% over the last week, with a monthly amount glided 3.08%, and seem to be holding up well over a long-time horizon.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored

On 23, November 2022, Sage Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference. In a post published today on Yahoo Finance, Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the Piper Sandler 34th Annual Healthcare Conference on Thursday, December 1, 2022, at 8:00 a.m. ET in New York, NY.

From an analyst’s perspective:

Sage Therapeutics Inc. [NASDAQ: SAGE] stock has seen the most recent analyst activity on November 01, 2022, when Loop Capital initiated its Hold rating and assigned the stock a price target of $41. Previously, Berenberg started tracking the stock with Hold rating on March 31, 2022, and set its price target to $37. On November 02, 2021, upgrade upgraded it’s rating to Buy but maintained its price target of $55 on the stock. Jefferies downgraded its rating to a Hold and reduced its price target to $50 on October 07, 2021. Needham started tracking with a Buy rating for this stock on September 23, 2021, and assigned it a price target of $84. In a note dated June 16, 2021, Citigroup downgraded an Neutral rating on this stock and revised its target price from $101 to $68.

Sage Therapeutics Inc. [SAGE] stock has fluctuated between $27.36 and $45.74 over the past year. Currently, Wall Street analysts expect the stock to reach $54.60 within the next 12 months. Sage Therapeutics Inc. [NASDAQ: SAGE] shares were valued at $37.45 at the most recent close of the market. An investor can expect a potential return of 45.79% based on the average SAGE price forecast.

Analyzing the SAGE fundamentals

Sage Therapeutics Inc. [NASDAQ:SAGE] reported sales of 1.74 billion for the most recent quarter, which represents a growth of 21.40%. Gross Margin for this corporation currently stands at +24.94% with Operating Margin at -7306.74%, Pretax Margin comes in at -7258.91%, and Net Margin reading is -7258.91%.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 36.89 points at the first support level, and at 36.32 for the second support level. However, for the 1st resistance point, the stock is sitting at 37.85, and for the 2nd resistance point, it is at 38.24.

Sage Therapeutics Inc. [SAGE] reported earnings per share of -$2.13 for its fiscal quarter that ended on 6/29/2022. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$2.15/share, meaning a difference of $0.02 and a surprise factor of 0.90%. By comparison, the stated earnings for the previous quarter ended on 3/30/2022 were -$2.07 per share as compared to estimates of -$2.04 per share, a difference of -$0.03 representing a surprise of -1.50%.

Ratios To Look Out For

For context, Sage Therapeutics Inc.’s Current Ratio is 14.70. On the other hand, the Quick Ratio is 21.14, and the Cash Ratio is 20.45. Considering the valuation of this stock, the price to sales ratio is 395.66, the price to book ratio is 1.45.

Transactions by insiders

Recent insider trading involved Greene Barry E, President and CEO, that happened on Nov 10 when 14500.0 shares were purchased. Director, Golumbeski George completed a deal on May 05 to buy 8000.0 shares.